Brief: Kala Bio Announces Topline Results From Chase Phase 2B Clinical Trial
29/09/2025 13:11
Sept 29 (Reuters) - KALA BIO Inc KALA.O: KALA BIO ANNOUNCES TOPLINE RESULTS FROM CHASE PHASE 2B CLINICAL TRIAL EVALUATING KPI-012 FOR THE TREATMENT OF PERSISTENT CORNEAL EPITHELIAL DEFECT (PCED) DID NOT MEET PRIMARY ENDPOINT KALA BIO INC - CHASE TRIAL FAILED TO ACHIEVE STATISTICAL SIGNIFICANCE FOR SECONDARY ENDPOINTS KALA BIO INC - KPI-012 TRIAL DID NOT MEET PRIMARY ENDPOINT KALA BIO INC - PLANS WORKFORCE REDUCTION AND COST-SAVING MEASURES KALA BIO INC - TO CEASE KPI-012 DEVELOPMENT, EVALUATE STRATEGIC OPTIONS Source text: ID:nGNX2C31b0 Further company coverage: KALA.O ((Reuters.Briefs@thomsonreuters.com;))